Yin, Tao
Wang, Guoping
Wang, Liuyang
Mudgal, Poorva
Wang, Ergang
Pan, Christopher C.
Alexander, Peter B.
Wu, Haiyang
Cao, Chengjie http://orcid.org/0009-0004-4734-3091
Liang, Yaosi http://orcid.org/0000-0002-3478-0864
Tan, Lianmei http://orcid.org/0000-0002-1445-4375
Huang, De
Chong, Mengyang
Chen, Rui
Lim, Bryan Jian Wei http://orcid.org/0000-0002-6048-2609
Xiang, Kun http://orcid.org/0000-0001-7793-4352
Xue, Wei
Wan, Lixin http://orcid.org/0000-0002-9759-5113
Hu, Hailan http://orcid.org/0000-0002-0425-5057
Loh, Yuin-Han http://orcid.org/0000-0002-4715-6454
Wang, Xiao-Fan http://orcid.org/0000-0001-7875-3940
Li, Qi-Jing http://orcid.org/0000-0002-0542-9784
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA249726, P01-CA225622, P50-CA190991, R01-CA249726)
The Biomedical Research Council (BMRC), A*STAR
Article History
Received: 29 March 2023
Accepted: 29 November 2023
First Online: 9 January 2024
Competing interests
: Q.-J.L. declares being a scientific co-founder and shareholder of TCRCure Biopharma and Hervor Therapeutics. The other authors declare no competing interests.